Downregulation of VEGF mRNA expression by triamcinolone acetonide acetate-loaded chitosan derivative nanoparticles in human retinal pigment epithelial cells

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4649-4660

  Zhou, Huaisheng ^a   Yang, Liqun ^b   Li, Huajie ^b   Gong, Haijun ^a   Cheng, Liangzheng ^b   Zheng, Haisheng ^a   Zhang, Li Ming ^b   Lan, Yuqing ^b  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chitosan; Human retinal pigment epithelial cells; mRNA; Nanoparticle; Triamcinolone acetonide acetate; Vascular endothelial growth factor

Indexed keywords

CHITOSAN; CORTICOSTEROID; DEOXYCHOLIC ACID; FLUORESCEIN ISOTHIOCYANATE; MESSENGER RNA; NANOPARTICLE; TRIAMCINOLONE ACETONIDE ACETATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BIOCOMPATIBILITY; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG LABELING; DRUG SYNTHESIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR IMAGING; PIGMENT EPITHELIUM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; ZETA POTENTIAL;

ACETATES; CELL LINE; CELL SHAPE; CELL SURVIVAL; CHITOSAN; DEOXYCHOLIC ACID; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; NANOPARTICLES; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; SOLUBILITY; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870363103     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29690     Document Type: Article

References (42)

1. Scanlon PH. Diabetic retinopathy. Medicine. 2010;38:656-660.
2. Fante RJ, Durairaj VD, Oliver SCN. Diabetic retinopathy: An update on treatment. Am J Med. 2010;123:213-216.
3. Alghadyan AA. Diabetic retinopathy-an update. Saudi J Ophthalmol. 2011;25:99-111.
4. Kim YH, Chung IY, Choi MY, etal. Triamcinolone suppresses retinal vascular pathology via a potent interruption of proinflammatory signal-regulated activation of VEGF during a relative hypoxia. Neurobiol Dis. 2007;26:569-576.
5. Chung HS, Harris A, Halter PJ, etal. Regional differences in retinal vascular reactivity. Invest Ophthalmol Vis Sci. 1999;40:2448-2453.
6. 164is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155-2162.
7. Funatsu H, Yamashita H, Noma H. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. Br J Ophthalmol. 2004;88:1064-1068.
8. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalance vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002;134:348-353.
9. Sydorova M, Lee MS. Vascular endothelial growth factor in virtreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res. 2005;37:l88-190.
10. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503-522.
11. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retinal Eye Res. 2005;24:587-611.
12. Ozdek SC, Aydin B, Gurelik G, Bahceci U, Hasanreisoglu B. Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion. Int Ophthalmol. 2006;16:27-34.
13. Kim YH, Choi MY, Kim YS, etal. Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. Life Sci. 2007;81:1167-1173.
14. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008;57:1026-1033.
15. Kim SY, Yang J, Lee YC, Park YH. Effect of a single intraoperative sub-Tenon injection of triamcinolone acetonide on the progression of diabetic retinopathy and visual outcomes after cataract surgery. J Cataract Refract Surg. 2008;34:823-826.
16. Oh J, Jung YS, Kim MY, etal. The effect of short-term exposure of triamcinolone acetonide on fibroblasts and retinal pigment epithelial cells. Acta Ophthalmol Scand. 2007;85:786-790.
17. Joans JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand. 2005; 83:645-663.
18. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60: 1650-1662.
19. Yang L, Kuang J, Wang J, Li Z, Zhang L. Loading and in vitro controlled release of indomethacin using amphiphilic cholesteryl-bearing carboxymethylcellulose derivatives. Macromol Biosci. 2008;8: 279-286.
20. Yang L, Zhang B, Wen L, Liang Q, Zhang L. Amphiphilic cholesteryl grafted sodium alginate derivative: Synthesis and self-assembly in aqueous solution. Carbohydr Polym. 2007;68:218-225.
21. Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2010;62:100-117.
22. Yang L, Lan Y, Guo H, etal. Ophthalmic drug-loaded N, O-carboxymethyl chitosan hydrogels: synthesis, in vitro and in vivo evaluation. Acta Pharmacol Sin. 2010;31:1625-1634.
23. Liu W, Hu M, Liu W, Xue C, Xu H, Yang X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm. 2008;364: 135-141.
24. Lee KY, Jo WH, Kwon IC, Kim YH, Jeong SY. Structural determination and interior polarity of self-aggregates prepared from deoxycholic acid-modified chitosan in water. Macromolecules. 1998;31:378-383.
25. Gottlieb HE, Kotlyar V, Nudelman A. NMR chemical shifts of common laboratory solvents as trace impurities. J Org Chem. 1997;62: 7512-7515.
26. Li XT, Zhang Y, Chen GQ. Nanofibrous polyhydroxyalkanoate matrices as cell growth supporting materials. Biomaterials. 2008;29: 3720-3728.
27. Wu J. Techniques and Applications of Modern FTIR Spectroscopy. Beijing, China: Science Press; 1994.
28. Kim C, Lee SC, Kang SW, Kwon IC, Kim YH, Jeong SY. Synthesis and the micellar characteristics of poly(ethylene oxide)-deoxycholic acid conjugates. Langmuir. 2000;16:4792-4797.
29. Luckachan GE, Pillai CKS. Chitosan/oligo L-lactide graft copolymers: effect of hydrophobic side chains on the physico-chemical properties and biodegradability. Carbohyr Polym. 2006;64:254-266.
30. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53-61.
31. Narayanan R, Mungcal JK, Kenney MC, Seigel GM, Kuppermann BD. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci. 2006;47: 722-728.
32. Yeung CK, Chan KP, Chiang SWY, Pang CP, Lam DSC. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci. 2003;44:5293-5300.
33. Nam HY, Kwon SM, Chung H, etal. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009;135:259-267.
34. Park JS, Han TH, Lee KY, etal. N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J Control Release. 2006;115:37-45.
35. Tomihata K, Ikada Y. In vitro and in vivo degradation of films of chitin and its deacetylated derivatives. Biomaterials. 1997;18:567-575.
36. Verheul RJ, Amidi M, Steenbergen MJ, Riet E, Jiskoot W, Hennink WE. Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. Biomaterials. 2009;30:3129-3135.
37. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
38. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629-5632.
39. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-1696.
40. Kim YS, Jung DH, Kim NH, etal. KIOM-79inhibits high glucose or AGEs-induced VEGF expression in human retinal pigment epithelial cells. J Ethnopharm. 2007;112:166-172.
41. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19cells under oxidative stress. Invest Ophthalmol Vis Sci. 2005;46:1062-1068.
42. Das S, Haddadi A, Veniamin S, Samuel J. Delivery of rapamycin-loaded nanoparticle down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34{thorn} progenitor-derived dendritic cells. J Biomed Mater Res. 2008;85A:983-992.